Genotoxicity of Metal-Based Antineoplastics
Author Information
Author(s): Carmen Socaciu, Ioan Pasca, Cristian Silvestru, Ionel Haiduc
Primary Institution: University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca
Hypothesis
The study investigates the mutagenic potential of two metal-based antineoplastic drugs compared to Cyclophosphamide.
Conclusion
The study found that Romcis and diphenylantimony(III) diisopropyldithiophosphate showed significant mutagenic potential, while Cyclophosphamide exhibited weaker effects.
Supporting Evidence
- Romcis and PADTF showed significant positive responses in the SOS Chromotest.
- Cyclophosphamide exhibited an indirect mutagenic potential amplified by metabolic activation.
- Chromosomal analysis revealed increased frequencies of chromosomal aberrations for RC and PADTF.
- The study compared the effects of two metal-based drugs with Cyclophosphamide using in vitro tests.
Takeaway
The researchers tested some cancer drugs to see if they could cause genetic damage, and found that two of them did a lot more damage than the others.
Methodology
The study used SOS Chromotest and cytogenetic analysis to evaluate the mutagenic potential of the drugs in bacterial and lymphocyte cultures.
Limitations
The study does not establish quantitative limits for clastogenicity and further investigations are needed.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website